Cardiac Assist Devices Market Size, Share & Industry Analysis, By Product Type (Ventricular Assist Devices, Intra-Aortic Balloon Pumps, Total Artificial Hearts, and Others), By Patient Group (Adult and Pediatric), By Indication (Bridge to Transplant (BTT), Bridge to Candidacy (BTC), Destination Therapy (DT), and Bridge to Recovery (BTR)), By End User (Hospitals and ASCs, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

The global cardiac assist devices market size was valued at USD 3.87 billion in 2025. The market is projected to grow from USD 4.29 billion in 2026 to USD 8.63 billion by 2034, exhibiting a CAGR of 9.1% during the forecast period.

The global market covers mechanical circulatory support technologies used when the heart cannot generate sufficient blood flow to meet the body's needs. The market includes ventricular assist devices, intra-aortic balloon pumps, total artificial hearts, and other qualifying systems used across temporary and long-term cardiac support. These devices play an important role in patients with advanced heart failure, cardiogenic shock, severe ventricular dysfunction, and those awaiting heart transplantation or recovering from acute cardiac events. Market growth is being supported by the increasing clinical burden of advanced heart disease, an aging population, continued shortages of donor hearts, and wider use of mechanical support in critical-care settings. At the same time, improvements in pump durability, hemocompatibility, miniaturization, percutaneous implantation, portable controllers, and patient monitoring are making cardiac support safer and more practical. Expansion of advanced heart-failure programs and mechanical circulatory support centers is further widening access to these therapies.

Furthermore, Johnson & Johnson, Abbott Laboratories, Getinge AB, and Teleflex Incorporated held the largest market share, driven by increased investments and strategic initiatives, including new product launches, collaborations, and partnerships.

CARDIAC ASSIST DEVICES MARKET TRENDS

Miniaturized, Percutaneous, and Connected Support Systems are Reshaping Cardiac Assist Therapy

Technology development is steadily moving cardiac assist devices toward smaller, less invasive, more durable, and increasingly connected platforms. Magnetically levitated continuous-flow pumps have become central to durable ventricular support as they reduce mechanical contact within the pump and are designed to improve long-term reliability and blood-handling characteristics. At the same time, percutaneous cardiac assist technologies are expanding the ability of clinicians to provide rapid temporary hemodynamic support without conventional surgical implantation.

Device manufacturers are also improving portable controllers, batteries, cannulation systems, monitoring capabilities, and blood-contacting surfaces. Connected platforms capable of transmitting operating information and supporting remote follow-up are becoming increasingly relevant as more patients live outside the hospital with long-term support. Development programs are also exploring wireless energy transfer and fully implantable configurations that could eventually reduce dependence on percutaneous drivelines. Together, these developments are gradually shifting the market from large, highly invasive support systems toward more compact and patient-centered mechanical circulatory support technologies.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Advanced Heart Failure and Cardiogenic Shock Burden to Increase Need for Mechanical Circulatory Support

The growing number of patients reaching advanced stages of heart failure is a major force behind demand for cardiac assist devices. Patients with severe ventricular dysfunction may no longer respond adequately to medication, revascularization, or conventional surgical treatment, creating a need for mechanical support to stabilize circulation. This requirement becomes particularly important in cardiogenic shock, where rapid deterioration can lead to multiorgan failure if adequate blood flow is not restored. Temporary devices such as intra-aortic balloon pumps and percutaneous ventricular support systems are increasingly incorporated into intensive-care and cardiac-intervention pathways. At the same time, durable VADs provide longer-term support for selected advanced-heart-failure patients.

Furthermore, the persistent gap between the number of patients requiring heart transplantation and the availability of donor hearts also strengthens demand for bridge-to-transplant and bridge-to-candidacy support. Consequently, growing disease severity, transplantation constraints, and expanding clinical familiarity with mechanical circulatory support are creating a durable underlying demand base for the market. American Heart Association (AHA) recognizes temporary mechanical circulatory support as an important option in cardiogenic shock and as a bridge to recovery, decision, or more durable support. These factors drive the global cardiac assist devices market growth.

MARKET RESTRAINTS

High Treatment Costs and Device-Related Complications Continue to Limit Wider Adoption

Despite substantial clinical value, cardiac assist devices remain among the more resource-intensive cardiovascular technologies used in modern healthcare. The cost extends beyond the device itself and includes implantation, intensive-care management, specialized surgical and heart-failure teams, perfusion support, follow-up, device management, and potential revision or replacement procedures. This limits adoption in healthcare systems where reimbursement is incomplete or advanced cardiac-care budgets remain constrained.

Additionally, clinical complications influence physician and patient decisions. Bleeding, thrombosis, stroke, infection, right-heart failure, hemolysis, device malfunction, and driveline-related complications can increase hospitalization and long-term treatment costs. Total artificial hearts and durable VADs also require careful patient selection because the potential benefit must outweigh substantial procedural and postoperative risks. Although newer pump designs have improved reliability and hemocompatibility, these therapies still require sophisticated multidisciplinary management. As a result, high total treatment costs, infrastructure requirements, and concerns surrounding adverse events continue to restrict penetration outside well-funded and highly specialized cardiac centers.

MARKET OPPORTUNITIES

Expansion of Advanced Cardiac Care in Emerging Markets is Opening New Commercial Opportunities

Emerging healthcare markets represent an increasingly important opportunity for cardiac assist device manufacturers as countries expand tertiary cardiac-care capacity and invest in advanced heart-failure treatment. Historically, implantation of durable VADs and other sophisticated circulatory-support technologies has been concentrated in North America, Western Europe, and Japan because of stronger reimbursement, established transplant programs, and specialized clinical infrastructure. This pattern is gradually changing. China and other Asian markets are developing domestic VAD platforms, expanding cardiac surgery capabilities, and increasing access to mechanical circulatory support.

Similar opportunities are emerging in selected hospitals across India, Southeast Asia, Latin America, and the Middle East as intensive-care capacity, insurance coverage, physician training, and high-complexity cardiac procedures increase. Local manufacturing may also improve affordability and reduce dependence on imported devices. Manufacturers that establish clinical-training programs, distribution partnerships, local regulatory capabilities, and appropriately priced product portfolios could gain early advantages. The opportunity therefore extends beyond additional unit sales to long-term development of cardiac-assist ecosystems in currently underpenetrated markets.

MARKET CHALLENGES

Complex Patient Selection May Restrict the Scalability of Cardiac Assist Programs

One of the market's most persistent challenges is that successful cardiac assist therapy depends on much more than device availability. Appropriate patients must be identified at the correct stage of disease, assessed for transplant eligibility or recovery potential, and matched with the most suitable form of temporary or durable support. Delayed referral can increase procedural risk, while overly aggressive use in patients unlikely to benefit can create poor clinical and economic outcomes. Hospitals must also maintain multidisciplinary teams involving advanced-heart-failure cardiologists, cardiothoracic surgeons, interventional cardiologists, perfusionists, intensivists, nurses, rehabilitation professionals, and device coordinators. Such capabilities remain concentrated in major tertiary centers, particularly in developing healthcare systems.

Segmentation Analysis

By Product Type

Broad Therapeutic Utility and High Device Value to Sustain the Leading Share of Ventricular Assist Devices Segment

Based on product type, the market is segmented into ventricular assist devices, intra-aortic balloon pumps, total artificial hearts, and others.

The ventricular assist devices segment accounted for the dominant share of the cardiac assist devices market share in 2025. The segment addresses both temporary and durable circulatory-support requirements and carries substantially higher value per treatment than many alternative support devices. VADs are used in patients with advanced refractory ventricular failure as bridge-to-transplant, bridge-to-candidacy, destination therapy, and, in selected circumstances, bridge-to-recovery.

The total artificial hearts segment is projected to grow at a CAGR of 12.8% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Patient Group

High Advanced-Heart-Failure Burden and Greater Procedure Volumes Keep Adults Segment as the Dominant Patient Group

By patient group, the market is classified into adult and pediatric.

The adult segment accounted for the leading share of the market in 2025, as advanced heart failure, ischemic cardiomyopathy, cardiogenic shock, and other forms of severe ventricular dysfunction occur predominantly in the adult population. Most durable VAD implantation programs, heart-transplant pathways, and temporary mechanical circulatory support procedures are therefore designed primarily around adult patients. Moreover, the segment is projected to hold a 96.6% share by 2026.

The pediatric segment is estimated to grow at a CAGR of 9.8% during the forecast period.

By Indication

Broad Use of Temporary Circulatory Support in Reversible Cardiac Failure to Support Bridge to Recovery (BTR)  Segment’s Growth

By indication, the market is classified into Bridge to Transplant (BTT), Bridge to Candidacy (BTC), Destination Therapy (DT), and Bridge to Recovery (BTR).

The Bridge to Recovery (BTR) segment accounted for the leading market share in 2025. These devices are frequently used to stabilize patients experiencing cardiogenic shock, acute myocardial dysfunction, post-cardiotomy failure, or other potentially reversible conditions. At the same time, clinicians treat the underlying cause and assess myocardial recovery. Moreover, the segment is projected to hold a 49.0% share in 2026.

The Bridge to Candidacy (BTC) segment is estimated to grow at a CAGR of 8.5% during the forecast period.

By End User

Concentration of Implantation and Critical-Care Infrastructure to Support Hospitals & ASCs Segment’s Leadership

Based on the end user, the market is classified into hospitals and ASCs, specialty clinics, and others.

The hospitals & ASCs segment accounted for the dominant share of the market in 2025. Implantation and management of VADs, total artificial hearts, and most temporary mechanical circulatory support systems require operating rooms or catheterization laboratories, cardiac ICUs, advanced imaging, perfusion capabilities, and continuous hemodynamic monitoring. Furthermore, the segment is set to hold a 91.9% share by 2026.

The specialty clinics segment is projected to grow at a CAGR of 10.1% during the forecast period.

Cardiac Assist Devices Market Regional Outlook

Based on region, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the largest revenue share in 2024, at USD 2.32 billion, and maintained its leading position at USD 2.57 billion in 2025. The region’s market growth is due to well-established advanced heart failure, cardiac surgery, and transplant infrastructure. The U.S. has a large network of tertiary hospitals and mechanical circulatory support centers capable of performing complex VAD implantation and managing patients requiring temporary cardiac support. Favorable reimbursement for qualifying ventricular assist device procedures, high healthcare expenditure, and relatively early adoption of new technologies such as percutaneous ventricular support and magnetically levitated pumps further support demand.

U.S. Cardiac Assist Devices Market

In 2026, the U.S. market is projected to represent USD 2.74 billion, capturing 63.8% of total global revenue.

Europe

Europe is expected to record a growth rate of 7.7% in the coming years, the second-highest globally, reaching USD 0.65 billion by 2026. Europe is expected to record steady growth as established cardiac surgery and transplant programs continue to adopt advanced mechanical circulatory support technologies. Countries such as Germany, the U.K., France, Italy, and Spain have established heart-failure centers, transplant hospitals, and reimbursement systems that support the clinical use of ventricular assist devices and temporary cardiac support.

U.K. Cardiac Assist Devices Market

The U.K. market size is projected to reach USD 0.12 billion by 2026, accounting for 2.9% of global revenue.

Germany Cardiac Assist Devices Market

Germany's market size is estimated to reach about USD 0.16 billion by 2026, representing roughly 3.7% of global revenue.

Asia Pacific

In 2026, the Asia Pacific market is predicted to be valued at USD 0.66 billion, ranking as the second-largest globally. Asia Pacific is likely to be one of the fastest-growing regions, supported by rapidly expanding cardiovascular-care infrastructure and increasing access to advanced heart-failure treatment. China is becoming particularly important due to the commercialization of domestically developed ventricular assist devices and increasing availability of mechanical circulatory support programs.

Japan Cardiac Assist Devices Market

The market in Japan is projected to generate approximately USD 0.20 billion in revenue by 2026, contributing nearly 4.7% to the global market.

China Cardiac Assist Devices Market

China’s market size is projected to reach approximately USD 0.19 billion by 2026, contributing about 4.5% to global revenues.

India Cardiac Assist Devices Market

India is forecast to contribute approximately USD 0.05 billion to the market by 2026, corresponding to about 1.2% of global revenues.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa regions are anticipated to witness moderate market growth, with Latin America expected to reach around USD 0.10 billion by 2026. Latin America is expected to show gradual growth as access to advanced cardiovascular treatment improves from a relatively low installed base. Brazil and Mexico are the major contributors, supported by large patient populations, expanding private hospital networks, and growing investment in tertiary cardiac-care facilities.

The Middle East & Africa market is expected to expand as governments and private healthcare groups increase investment in tertiary hospitals, cardiac surgery, intensive care, and transplant-related infrastructure. Growth is likely to be led by GCC countries, where comparatively high healthcare spending, hospital modernization programs, medical tourism, and adoption of advanced medical technologies support demand for sophisticated cardiac assist systems.

GCC Cardiac Assist Devices Market

By 2026, the GCC market size is expected to reach approximately USD 0.03 billion, accounting for nearly 0.8% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Product Performance, Regulatory Approvals, and Technological Innovation by Key Players to Boost Market Competition

The global cardiac assist devices market is moderately concentrated, with a few companies holding strong positions in major product categories. Johnson & Johnson (Abiomed) and Abbott Laboratories lead the market through established ventricular assist and temporary circulatory support platforms. At the same time, Getinge and Teleflex maintain significant positions in intra-aortic balloon pump systems.

The competitive landscape is becoming more diverse as regional manufacturers such as Suzhou Tongxin Medical Technology, and Shenzhen Core Medical Technology expand their presence, particularly in China and other Asian markets. Companies such as Berlin Heart, SynCardia, and CARMAT remain important in pediatric VADs and total artificial heart technologies.

Competition is primarily driven by product performance, clinical outcomes, regulatory approvals, technological innovation, physician adoption, pricing, reimbursement access, and the ability to build strong relationships with advanced heart-failure and transplant centers.

LIST OF KEY CARDIAC ASSIST DEVICES COMPANIES PROFILED

• Johnson & Johnson (U.S.)
• Abbott Laboratories (U.S.)
• Getinge AB (Sweden)
• Teleflex Incorporated (U.S.)
• SENKO Medical Instrument Mfg. Co., Ltd. (Japan)
• Berlin Heart GmbH (Germany)
• Suzhou Tongxin Medical Technology Co., Ltd. (China)
• Shenzhen Core Medical Technology Co., Ltd. (China)
• SynCardia Systems, LLC (U.S.)
• CARMAT SAS (France)

KEY INDUSTRY DEVELOPMENTS

• May 2026: ROCOR MEDICAL Technology, TEDA International Cardiovascular Hospital, and Israeli medical-technology expert Michael Zilbershlag signed a strategic cooperation agreement to develop Transcutaneous Energy Transfer (TET) technology for artificial hearts.
• April 2026: BrioHealth received FDA conditional approval to initiate the Brio4Kids clinical evaluation of BrioVAD in pediatric patients with advanced heart failure under the existing INNOVATE IDE.
• October 2025: J&J showcased the ninth-generation Impella CP at TCT 2025. The latest iteration incorporates design updates intended to optimize functionality and ease of use, extending the company's long-running development of percutaneous temporary ventricular support.
• May 2025: The FDA granted the BiVACOR Total Artificial Heart Breakthrough Device Designation, recognizing its potential to address severe biventricular heart failure in patients with limited therapeutic alternatives.
• April 2025: Teleflex received FDA 510(k) clearance for the AC3 Range intra-aortic balloon pump. The transport-focused IABP incorporates dual power options, a full-size helium tank, reinforced mobility features, and compatibility with ambulance and fixed- or rotary-wing aircraft transport.

REPORT COVERAGE

The report provides an in-depth analysis of all market segments, highlighting key drivers, trends, opportunities, restraints, and challenges. It also provides insights into technological advancements, key industry developments, company market share analysis, and profiles of leading companies. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom-Up Approaches

Approach 1: Revenues and Market Share of Major Cardiac Assist Device Players

• Collection of cardiac-assist-device-attributable revenues from annual reports, SEC filings, investor presentations, company disclosures, and product portfolios of key manufacturers such as Johnson & Johnson (Abiomed), Abbott, Getinge, Teleflex, Berlin Heart, and other relevant players.
• Estimation of company market shares based on qualifying product revenues, geographic presence, product availability, installed base, hospital penetration, and commercialization status.
• Triangulation of company-level revenues with regional device utilization and clinical demand to derive the global market estimate.

Approach 2: Device-Level Volume and ASP Analysis

• Identification of major commercially available ventricular assist devices, intra-aortic balloon pumps, total artificial hearts, and other qualifying cardiac assist systems.
• Collection and estimation of annual device shipments, implantation/utilization volumes, installed base, replacement demand, and manufacturer-level average selling prices.
• Market value was estimated by multiplying qualifying device volumes by manufacturer ASPs across major countries and regions.
• Dedicated device components such as pumps, controllers, balloon catheters, cannulae, batteries, and accessories were included where commercially attributable.

Approach 3: Patient, Procedure and Clinical Demand Model

• Assessment of advanced/end-stage heart failure patients, cardiogenic shock cases, heart-transplant waitlists, transplant volumes, and eligible mechanical circulatory support populations.
• Mapping of patient demand across Bridge to Transplant, Bridge to Candidacy, Destination Therapy, and Bridge to Recovery.
• Analysis of VAD implantation, IABP utilization, transplant-center capacity, advanced-heart-failure centers, cardiac surgery infrastructure, reimbursement, and access to specialist care.
• Eligible patient/procedure volumes were combined with device utilization rates and ASPs to estimate country- and regional-level market values.

2. Top-Down Approach

Approach 1: Analysis of Parent Mechanical Circulatory Support / Cardiovascular Device Market

• Analysis of broader cardiovascular device and mechanical circulatory support spending across major countries and estimation of the proportion attributable specifically to qualifying cardiac assist devices.
• Market allocation was based on advanced-heart-failure burden, cardiogenic shock treatment, cardiac assist procedure volumes, transplant activity, device penetration, reimbursement, and product availability.
• ECMO, pacemakers, ICDs, CRT devices, structural heart products, and unrelated cardiovascular devices were excluded from the addressable market.
• The resulting estimates were validated against manufacturer revenues and bottom-up device volume × ASP calculations.

3. List of Key Sources

• Annual Reports, SEC Filings and Investor Presentations
• Company Product Catalogs and Regulatory Disclosures
• U.S. FDA and CMS
• European Commission / EU MDR sources
• PMDA / MHLW
• NMPA
• CDSCO
• TGA
• ISHLT
• STS / INTERMACS
• American Heart Association
• American College of Cardiology
• European Society of Cardiology
• National heart-transplant and heart-failure registries
• WHO
• OECD
• World Bank
• National health ministries and reimbursement authorities
• Product approvals, recalls, clinical studies, procurement data, and reimbursement updates

4. Primary Interviews

Supply-Side Interviews: 60%

• Key Respondents: Cardiac assist device manufacturers, distributors, suppliers, sales executives, marketing/product managers, regional business heads, clinical specialists, and device-industry experts.
• Discussions focused on market size, product sales, ASPs, device penetration, competitive positioning, distribution channels, regulatory developments, and expected adoption trends.

Demand-Side Interviews: 40%

• Key Respondents: Advanced-heart-failure cardiologists, cardiothoracic surgeons, interventional cardiologists, perfusionists, VAD coordinators, transplant-center professionals, ICU specialists, and hospital procurement executives.
• Discussions focused on device utilization, patient eligibility, clinical preference, implantation volumes, reimbursement, procurement patterns, treatment costs, and adoption across countries and regions.